135 related articles for article (PubMed ID: 16376858)
1. Characterization of enzymatic properties of human ribonucleotide reductase holoenzyme reconstituted in vitro from hRRM1, hRRM2, and p53R2 subunits.
Qiu W; Zhou B; Darwish D; Shao J; Yen Y
Biochem Biophys Res Commun; 2006 Feb; 340(2):428-34. PubMed ID: 16376858
[TBL] [Abstract][Full Text] [Related]
2. The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53.
Zhou B; Liu X; Mo X; Xue L; Darwish D; Qiu W; Shih J; Hwu EB; Luh F; Yen Y
Cancer Res; 2003 Oct; 63(20):6583-94. PubMed ID: 14583450
[TBL] [Abstract][Full Text] [Related]
3. Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits.
Xue L; Zhou B; Liu X; Qiu W; Jin Z; Yen Y
Cancer Res; 2003 Mar; 63(5):980-6. PubMed ID: 12615712
[TBL] [Abstract][Full Text] [Related]
4. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase.
Shao J; Zhou B; Zhu L; Qiu W; Yuan YC; Xi B; Yen Y
Cancer Res; 2004 Jan; 64(1):1-6. PubMed ID: 14729598
[TBL] [Abstract][Full Text] [Related]
5. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay.
Shao J; Zhou B; Zhu L; Bilio AJ; Su L; Yuan YC; Ren S; Lien EJ; Shih J; Yen Y
Biochem Pharmacol; 2005 Feb; 69(4):627-34. PubMed ID: 15670581
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer.
Liu X; Zhou B; Xue L; Yen F; Chu P; Un F; Yen Y
Clin Colorectal Cancer; 2007 Jan; 6(5):374-81. PubMed ID: 17311703
[TBL] [Abstract][Full Text] [Related]
7. Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.
Hsu NY; Wu JY; Liu X; Yen Y; Chen CY; Chou MC; Lin CH; Lee H; Cheng YW
Anticancer Res; 2011 Oct; 31(10):3475-81. PubMed ID: 21965764
[TBL] [Abstract][Full Text] [Related]
8. Redox property of ribonucleotide reductase small subunit M2 and p53R2.
Liu X; Xue L; Yen Y
Methods Mol Biol; 2008; 477():195-206. PubMed ID: 19082948
[TBL] [Abstract][Full Text] [Related]
9. A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase.
Shao J; Zhou B; Di Bilio AJ; Zhu L; Wang T; Qi C; Shih J; Yen Y
Mol Cancer Ther; 2006 Mar; 5(3):586-92. PubMed ID: 16546972
[TBL] [Abstract][Full Text] [Related]
10. Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2.
Zhou B; Su L; Yuan YC; Un F; Wang N; Patel M; Xi B; Hu S; Yen Y
Mol Cancer Ther; 2010 Jun; 9(6):1669-79. PubMed ID: 20484015
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and ribonucleotide reductase inhibitory activity of thiosemicarbazones.
Krishnan K; Prathiba K; Jayaprakash V; Basu A; Mishra N; Zhou B; Hu S; Yen Y
Bioorg Med Chem Lett; 2008 Dec; 18(23):6248-50. PubMed ID: 18976907
[TBL] [Abstract][Full Text] [Related]
12. Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells.
Liu X; Zhou B; Xue L; Shih J; Tye K; Lin W; Qi C; Chu P; Un F; Wen W; Yen Y
Clin Cancer Res; 2006 Nov; 12(21):6337-44. PubMed ID: 17085643
[TBL] [Abstract][Full Text] [Related]
13. Bcl2 induces DNA replication stress by inhibiting ribonucleotide reductase.
Xie M; Yen Y; Owonikoko TK; Ramalingam SS; Khuri FR; Curran WJ; Doetsch PW; Deng X
Cancer Res; 2014 Jan; 74(1):212-23. PubMed ID: 24197132
[TBL] [Abstract][Full Text] [Related]
14. Structurally dependent redox property of ribonucleotide reductase subunit p53R2.
Xue L; Zhou B; Liu X; Wang T; Shih J; Qi C; Heung Y; Yen Y
Cancer Res; 2006 Feb; 66(4):1900-5. PubMed ID: 16488986
[TBL] [Abstract][Full Text] [Related]
15. 2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase .
Smith P; Zhou B; Ho N; Yuan YC; Su L; Tsai SC; Yen Y
Biochemistry; 2009 Nov; 48(46):11134-41. PubMed ID: 19728742
[TBL] [Abstract][Full Text] [Related]
16. The structural basis for the allosteric regulation of ribonucleotide reductase.
Ahmad MF; Dealwis CG
Prog Mol Biol Transl Sci; 2013; 117():389-410. PubMed ID: 23663976
[TBL] [Abstract][Full Text] [Related]
17. Potent competitive inhibition of human ribonucleotide reductase by a nonnucleoside small molecule.
Ahmad MF; Alam I; Huff SE; Pink J; Flanagan SA; Shewach D; Misko TA; Oleinick NL; Harte WE; Viswanathan R; Harris ME; Dealwis CG
Proc Natl Acad Sci U S A; 2017 Aug; 114(31):8241-8246. PubMed ID: 28716944
[TBL] [Abstract][Full Text] [Related]
18. Protein properties of the subunits of ribonucleotide reductase and the specificity of the allosteric site(s).
Cory JG; Sato A; Brown NC
Adv Enzyme Regul; 1986; 25():3-19. PubMed ID: 3544706
[TBL] [Abstract][Full Text] [Related]
19. A quantitative model for allosteric control of purine reduction by murine ribonucleotide reductase.
Scott CP; Kashlan OB; Lear JD; Cooperman BS
Biochemistry; 2001 Feb; 40(6):1651-61. PubMed ID: 11327824
[TBL] [Abstract][Full Text] [Related]
20. Nucleoside Analogue Triphosphates Allosterically Regulate Human Ribonucleotide Reductase and Identify Chemical Determinants That Drive Substrate Specificity.
Knappenberger AJ; Ahmad MF; Viswanathan R; Dealwis CG; Harris ME
Biochemistry; 2016 Oct; 55(41):5884-5896. PubMed ID: 27634056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
